This has potential !! Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE: MVMD) (FRA: 20MP) is pleased to announce that it has successfully completed its initial safety pre-clinical validation of its solubilized Ivermectin technology. The trial was conducted to demonstrate the safety and efficacy of the Company's recent invention which enables Ivermectin (among other drugs) to become water-soluble without the use of harmful organic solvents, improving its water solubility by nearly 5,000 times*.
The pre-clinical canine trial was conducted by a third party preclinical contract research organization ("CRO") and tested the solubilized Ivermectin via both an intramuscular injection and applied to rapid dissolve oral strips with the Company's patented Quicksome™ desiccated liposome technology compared to existing oral and subcutaneous injection solutions. The results demonstrated a significant improvement in the pharmacokinetic performance of the soluble ivermectin technology with no adverse side effects as described below.
"We now have the best pharmacokinetic data for Ivermectin in the world and the implications for both human and animal health are tremendous," stated Mike Farber, Director of Life Sciences at Mountain Valley MD. "MVMD has succeeded in making a Nobel prize winning wonder drug even better based on overcoming its number one limitation of solubility."